

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Last Update: Mar 06, 2025

A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

ClinicalTrials.gov Identifier:

[NCT05639114](#)

Novartis Reference Number: CVAY736F12301

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The trial will evaluate efficacy, safety and tolerability of two regimens of Ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE). A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of Ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)

Condition

Systemic Lupus Erythematosus

Phase

Phase3

Overall Status

Recruiting

Number of Participants

406

Start Date

Mar 02, 2023

Completion Date

Apr 20, 2029

Gender

All

Age(s)

12 Years - 100 Years (Child, Adult, Older Adult)

Interventions

Drug

Ianalumab

ianalumab s.c. monthly or quarterly

Drug

Placebo

placebo s.c. monthly

Eligibility Criteria

Inclusion Criteria:

- * Male and female participants aged 12 years or older at the time of screening, or limited to 18 years or older in European Economic Area countries and other countries where inclusion of participants below 18 years is not allowed.
- * Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to screening.
- * Elevated serum titers at screening of anti-nuclear antibodies $\geq 1:80$ as determined by a central laboratory with a SLE-typical fluorescence pattern.
- * Currently receiving CS and/or anti-malarial treatment and/or another disease-modifying antirheumatic drug (DMARD) as specified in the protocol.
- * SLEDAI-2K criteria at screening: SLEDAI-2K score ≥ 6 points, excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome"
- * BILAG-2004 disease activity level at screening of at least 1 of the following:
 - * BILAG-2004 level 'A' disease in ≥ 1 organ system, Or
 - * BILAG-2004 level 'B' disease in ≥ 2 organ systems
 - * Weigh at least 35 kg at screening

Exclusion Criteria:

- * Prior treatment with ianalumab
- * History of receiving following treatment: I) high dose CS, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) administered within 12 weeks prior to screening. II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell activating factor (BAFF)-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) any B cell-depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). IV) Traditional Chinese medicines administered within 30 days prior to randomization.
- * Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection

- * Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- * Evidence of active tuberculosis infection
- * History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result at screening
- * Any one of the following abnormal laboratory values prior to randomization
- * Platelets $< 25000/\text{mm}^3$ ($< 25 \times 10^3/\mu\text{L}$)
- * Hemoglobin (Hgb) $< 8.0 \text{ g/dL}$ ($< 5 \text{ mmol/L}$), or $< 7.0 \text{ g/dL}$ ($< 4.3 \text{ mmol/L}$) if related to participant's SLE such as in active hemolytic anaemia
- * Absolute neutrophil count (ANC) ($< 0.8 \times 10^3/\mu\text{L}$)
- * Severe organ dysfunction or life-threatening disease at screening
- * Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.0 mg/dL (176.84 $\mu\text{mol/L}$), or requiring immune-suppressive induction or maintenance treatment at screening
- * Receipt of live/attenuated vaccine within a 4-week period before first dosing
- * Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms
- * Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS
- * History of malignancy of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer
- * Pregnant or nursing (lactating) women.
- * Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while on study treatment and for 6 months after stopping of investigational drug.
- * Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study

Brazil

Novartis Investigative Site

Recruiting

Rio de Janeiro,RJ,22211 230,Brazil

Novartis Investigative Site

Recruiting

Barretos,Sao Paulo,14784 400,Brazil

Novartis Investigative Site

Recruiting

Salvador,BA,40150 150,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,01244-030,Brazil

Novartis Investigative Site

Recruiting

Vitoria,ES,29055 450,Brazil

Novartis Investigative Site

Recruiting

Sao Paulo,SP,04038-002,Brazil

Novartis Investigative Site

Recruiting

Belo Horizonte,MG,30150-221,Brazil

Novartis Investigative Site

Recruiting

Salvador,40301-155,Brazil

Novartis Investigative Site

Recruiting

Curitiba,PR,80030-110,Brazil

Novartis Investigative Site

Recruiting

Niteroi,RJ,24020 096,Brazil

Bulgaria

Novartis Investigative Site

Recruiting

Ruse,7002,Bulgaria

Novartis Investigative Site

Recruiting

Sofia,1680,Bulgaria

Novartis Investigative Site

Recruiting

Plovdiv,4002,Bulgaria

Canada

Novartis Investigative Site

Recruiting

Calgary,Alberta,T2n 4z6,Canada

Novartis Investigative Site

Recruiting

Vancouver,British Columbia,V5z 1l7,Canada

Novartis Investigative Site

Recruiting

Hamilton,Ontario,L8n 3z5,Canada

Novartis Investigative Site

Recruiting

Toronto,Ontario,M5t 2s8,Canada

Novartis Investigative Site

Recruiting

Rimouski,Quebec,G5l 5t1,Canada

China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510000,China

Novartis Investigative Site

Recruiting

Shanghai,200040,China

Novartis Investigative Site

Recruiting

Suzhou,Jiangsu,215004,China

Novartis Investigative Site

Recruiting

Guangzhou,Guangdong,510080,China

Novartis Investigative Site

Recruiting

Shanghai,200127,China

Novartis Investigative Site

Recruiting

Nanchang,Jiangxi,330006,China

Novartis Investigative Site

Recruiting

Shantou,Guangdong,515041,China

Novartis Investigative Site

Recruiting

Zhejiang,315016,China

Novartis Investigative Site

Recruiting

Pingxiang,Jiangxi,337000,China

Novartis Investigative Site

Recruiting

Haikou,Hainan,570311,China

Novartis Investigative Site

Recruiting

Chang Chun,Jilin,130021,China

Novartis Investigative Site

Recruiting

Zhuzhou,Hunan,412000,China

Novartis Investigative Site

Recruiting

Urumqi,Xinjiang,830001,China

Novartis Investigative Site

Recruiting

Linyi,Shandong,276000,China

Novartis Investigative Site

Recruiting

Wenzhou,Zhejiang,325000,China

Novartis Investigative Site

Recruiting

Baotou,Inner Mongolia,014010,China

Novartis Investigative Site

Recruiting

Beijing,100069,China

Novartis Investigative Site

Recruiting

Chengdu,Sichuan,610041,China

Novartis Investigative Site

Recruiting

Nanjing,Jiangsu,210008,China

Novartis Investigative Site

Recruiting

Xinxiang,453099,China

Novartis Investigative Site

Recruiting

Beijing,100730,China

Czechia

Novartis Investigative Site

Recruiting

Brno,63800,Czechia

Novartis Investigative Site

Recruiting

Praha 2,128 50,Czechia

Novartis Investigative Site

Recruiting

Uherske Hradiste,686 01,Czechia

Guatemala

Novartis Investigative Site

Recruiting

Guatemala,01010,Guatemala

Novartis Investigative Site

Recruiting

Guatemala City,01011,Guatemala

Hungary

Novartis Investigative Site

Recruiting

Budapest,1036,Hungary

Novartis Investigative Site

Recruiting

Szekesfehervar,Fejer,8000,Hungary

Novartis Investigative Site

Recruiting

Gyula,5700,Hungary

Israel

Novartis Investigative Site

Recruiting

Haifa,3109601,Israel

Novartis Investigative Site

Recruiting

Ramat Gan,52621,Israel

Japan

Novartis Investigative Site

Recruiting

Bunkyo ku,Tokyo,113 8655,Japan

Novartis Investigative Site

Recruiting

Kawasaki,Kanagawa,216-8511,Japan

Novartis Investigative Site

Recruiting

Kitakyushu,Fukuoka,807-8556,Japan

Novartis Investigative Site

Recruiting

Chiba,2608677,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,457 8510,Japan

Novartis Investigative Site

Recruiting

Bunkyo ku,Tokyo,113-8431,Japan

Novartis Investigative Site

Recruiting

Yokohama-city,Kanagawa,236-0004,Japan

Novartis Investigative Site

Recruiting

Sendai city,Miyagi,983 8512,Japan

Novartis Investigative Site

Recruiting

Fukuoka,815-8555,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,457-8511,Japan

Novartis Investigative Site

Recruiting

Bunkyo-ku,Tokyo,113-8519,Japan

Novartis Investigative Site

Recruiting

Yokohama,Kanagawa,222-0036,Japan

Novartis Investigative Site

Recruiting

Shinjuku-ku,Tokyo,160 8582,Japan

Novartis Investigative Site

Recruiting

Gifu,500-8717,Japan

Novartis Investigative Site

Recruiting

Ichikawa,Chiba,272 8516,Japan

Novartis Investigative Site

Recruiting

Chuo ku,Tokyo,104 8560,Japan

Novartis Investigative Site

Recruiting

Kurashiki,Okayama,710-8522,Japan

Novartis Investigative Site

Recruiting

Miyazaki,889-1692,Japan

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,812-8582,Japan

Novartis Investigative Site

Recruiting

Fuchu-city,Tokyo,183-8561,Japan

Novartis Investigative Site

Recruiting

Suita,Osaka,565 0871,Japan

Novartis Investigative Site

Recruiting

Osaka,545-8586,Japan

Novartis Investigative Site

Recruiting

Sapporo city,Hokkaido,060 8648,Japan

Novartis Investigative Site

Recruiting

Fuchu,Tokyo,183-8524,Japan

Novartis Investigative Site

Recruiting

Iruma-gun,Saitama,350-0495,Japan

Novartis Investigative Site

Recruiting

Itabashi-ku,Tokyo,173-8610,Japan

Novartis Investigative Site

Recruiting

Ono,Hyogo,675-1327,Japan

Novartis Investigative Site

Recruiting

Meguro,Tokyo,153-8515,Japan

Poland**Novartis Investigative Site**

Recruiting

Bydgoszcz,85 168,Poland

Novartis Investigative Site

Recruiting

Bydgoszcz,85-065,Poland

Novartis Investigative Site

Recruiting

Bytom,41 902,Poland

Novartis Investigative Site

Recruiting

Lodz,90-338,Poland

Novartis Investigative Site

Recruiting

Rzeszow,35 301,Poland

Novartis Investigative Site

Recruiting

Warszawa,00-874,Poland

Novartis Investigative Site

Recruiting

Wroclaw,Dolnoslaskie,52-210,Poland

Novartis Investigative Site

Recruiting

Warszawa,04141,Poland

Portugal

Novartis Investigative Site

Recruiting

Braga,4710243,Portugal

Novartis Investigative Site

Recruiting

Leiria,2410-104,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1050-034,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1349-019,Portugal

Novartis Investigative Site

Recruiting

Lisboa,1649 035,Portugal

Singapore

Novartis Investigative Site

Recruiting

Singapore,169608,Singapore

Novartis Investigative Site

Recruiting

Singapore,S308433,Singapore

Novartis Investigative Site

Recruiting

Singapore,119074,Singapore

Slovakia

Novartis Investigative Site

Recruiting

Kosice,04011,Slovakia

Novartis Investigative Site

Recruiting

Piestany,92101,Slovakia

Novartis Investigative Site

Recruiting

Bratislava,85101,Slovakia

South Africa

Novartis Investigative Site

Recruiting

Umhlanga,4320,South Africa

Novartis Investigative Site

Recruiting

Cape Town,7405,South Africa

Novartis Investigative Site

Recruiting

Panorama,7500, South Africa

Novartis Investigative Site

Recruiting

Pretoria,0002, South Africa

Novartis Investigative Site

Recruiting

Stellenbosch,7600, South Africa

Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08035, Spain

Novartis Investigative Site

Recruiting

Vigo,Pontevedra,36200, Spain

Novartis Investigative Site

Recruiting

Valencia,Comunidad Valenciana,46014, Spain

Novartis Investigative Site

Recruiting

Elche,Alicante,03203, Spain

Novartis Investigative Site

Recruiting

La Laguna,Santa Cruz De Tenerife,38320, Spain

Novartis Investigative Site

Recruiting

Badajoz,Extremadura,06080, Spain

Novartis Investigative Site

Recruiting

Santander,Cantabria,39008,Spain

Novartis Investigative Site

Recruiting

Madrid,28034,Spain

Novartis Investigative Site

Recruiting

Santiago De Compostela,Galicia,15706,Spain

Novartis Investigative Site

Recruiting

Valladolid,Castilla Y Leon,47012,Spain

Novartis Investigative Site

Recruiting

San Sebastian de los Reyes,Madrid,28702,Spain

Novartis Investigative Site

Recruiting

Badalona,Catalunya,08916,Spain

Novartis Investigative Site

Recruiting

Pamplona,Navarra,31008,Spain

Novartis Investigative Site

Recruiting

Barcelona,Catalunya,08003,Spain

Novartis Investigative Site

Recruiting

Vitoria Gasteiz,Pais Vasco,01009,Spain

Thailand

Novartis Investigative Site

Recruiting

Chiang Mai,50200,Thailand

Novartis Investigative Site

Recruiting

Songkhla,Hat Yai,90110,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10400,Thailand

Novartis Investigative Site

Recruiting

Bangkok,10700,Thailand

Turkey

Novartis Investigative Site

Recruiting

Ankara,06500,Turkey

Novartis Investigative Site

Recruiting

Aydin,09100,Turkey

Novartis Investigative Site

Recruiting

Etlik Ankara,06018,Turkey

Novartis Investigative Site

Recruiting

Izmir,35620,Turkey

Novartis Investigative Site

Recruiting

Konya,42080,Turkey

United States

Prisma Health

Recruiting

Columbia,South Carolina,29203,United States

Laketa Hillman-Daughety

Email: laketa.hillman-daughety@prismahealth.org

Sunita Paudyal

Robert A Hozman MD SC

Recruiting

Skokie,Illinois,60076,United States

Robert Hozman

Iryna Shevchuk

Phone: [847-727-2743](tel:847-727-2743)

Email: ishevchuk@cisresearch.com

Epic Medical Research

Recruiting

Red Oak,Texas,75154,United States

Harshini Potluri

Phone: [469-206-2642](tel:469-206-2642)

Email: hpotluri@epicmedresearch.com

Sunny Patel

Univ of Nevada School of Med

Recruiting

Las Vegas,Nevada,89102,United States

Katherin Mendez

Phone: [702-671-5093](tel:702-671-5093)

Email: katherin.mendez@unlv.edu

Walter Winn Chatham

GNP Research

Recruiting

Hollywood,Florida,33024,United States

Rossana Villaverde

Phone: [754-248-3538](tel:754-248-3538)

Email: rossana@gnpresearch.com

Mark Jaffe

Sahni Rheumatology and Therapy

Recruiting

West Long Branch,New Jersey,07764,United States

Sachit Sudharshan

Phone: [732-272-1456](tel:732-272-1456)

Email: manager@sahnirheumatology.com

Kiren Sahni

University of California San Diego

Recruiting

La Jolla,California,92093,United States

Chelsey J F Smith

Phone: [+1 858 657 7040](tel:+18586577040)

Providence Medical Center

Recruiting

Burbank,California,91505,United States

Elyza Carvajal

Phone: [818-869-7600](tel:818-869-7600)

Email: elyza.carvajal@providence.org

Sue Chung

Lake Cumberland Rheumatology and In

Recruiting

New Albany, Indiana, 47150, United States

Kara Lay

Email: klay@lcrheumatology.com

Scott Lewis

University Of Miami

Recruiting

Miami, Florida, 33136, United States

Maria Fernanda Carpintero

Priscilla Madero

Phone: [305-243-2568](tel:305-243-2568)

Email: pdm73@med.miami.edu

NYU Langone Health

Recruiting

Brooklyn, New York, 11201, United States

David Goddard

Tiaja Dowdy

Email: tiaja.dowdy@nyulangone.org

Keck School of Medicine

Recruiting

Los Angeles, California, 90033, United States

Leanna Wise

Sara Madrigal

Phone: [323-442-1963](tel:323-442-1963)

Email: smadriga@usc.edu

Clinical Research of West Florida Inc

Recruiting

Tampa,Florida,33603,United States

John Carter

Sara Allison

Phone: 813-870-1292

Email: sallison@crwf.com

STAT Research Inc

Recruiting

Dayton,Ohio,45402,United States

Derek Tipton

Phone: 937-223-4229

Email: Derek@StatResearch.net

Sanford Wolfe

Millennium Clinical Trials

Recruiting

Westlake Village,California,91361,United States

Elvira Lindwall

Ochsner Clinic Foundation

Recruiting

Baton Rouge,Louisiana,70836,United States

Saravanan Thiagarajan

Stephanie Fontenot

Phone: 225-761-5481

Email: Stephanie.fontenot@ochsner.org

Parris and Associates Rheumatology

Recruiting

Lawrenceville,Georgia,30044,United States

Phone: +17709621616#8334

Glenn Parris

Texas Arthritis Center

Recruiting

El Paso,Texas,79902,United States

Sanjay Chabra

Medical Center Main Campus

Recruiting

Cleveland,Ohio,44109,United States

Maggie Washington

Phone: 216-778-7800

Email: mwashington3@metrohealth.org

Nora Singer

University of Colorado

Recruiting

Aurora,Colorado,80045,United States

Christopher Striebich

Najeeb Arishi

Email: najeeb.arishi@cuanschutz.edu

Clinical Res Of W Florida

Recruiting

Clearwater,Florida,33765,United States

Robert Levin

Sydney K Mullen

Phone: 727-466-0078

Email: smullen@crwf.com

Shelby Research LLC

Recruiting

Memphis,Tennessee,38119,United States

Ramesh C Gupta

Tanuja Katiki

Email: shelbyres19@outlook.com

Paramount Med Rsrch and Consult LLC

Recruiting

Middleburg Heights, Ohio, 44130, United States

Diane Peplin

Phone: [440-891-9395](tel:440-891-9395)

Email: dianepeplin@hotmail.com

Isam Diab

Henry Ford Health

Recruiting

Detroit, Michigan, 48202, United States

Alireza Meysami

Accurate Clinical Research Research

Recruiting

Baytown, Texas, 77521, United States

Sabeen Najam

Yale University School Of Medicine

Recruiting

New Haven, Connecticut, 06520, United States

Fotios Koumpouras

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email:

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://uat2.arctic.novartis.com/clinicaltrials/study/nct05639114>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT05639114>
2. [#trial-eligibility](#)
3. <mailto:laketa.hillman-daughety@prismahealth.org>
4. <tel:847-727-2743>
5. <mailto:ishevchuk@cisresearch.com>
6. <tel:469-206-2642>
7. <mailto:hpotluri@epicmedresearch.com>
8. <tel:702-671-5093>
9. <mailto:katherin.mendez@unlv.edu>
10. <tel:754-248-3538>
11. <mailto:rossana@gnpresearch.com>
12. <tel:732-272-1456>
13. <mailto:manager@sahnirheumatology.com>
14. [tel:+1 858 657 7040](tel:+18586577040)
15. <tel:818-869-7600>
16. <mailto:elyza.carvajal@providence.org>
17. <mailto:klay@lcrheumatology.com>
18. <tel:305-243-2568>
19. <mailto:pdm73@med.miami.edu>
20. <mailto:tiaja.dowdy@nyulangone.org>
21. <tel:323-442-1963>
22. <mailto:smadriga@usc.edu>
23. <tel:813-870-1292>
24. <mailto:sallison@crwf.com>
25. <tel:937-223-4229>
26. <mailto:Derek@StatResearch.net>
27. <tel:225-761-5481>
28. <mailto:Stephanie.fontenot@ochsner.org>
29. <tel:+17709621616#8334>
30. <tel:216-778-7800>
31. <mailto:mwashington3@metrohealth.org>
32. <mailto:najeeb.arishi@cuanschutz.edu>
33. <tel:727-466-0078>
34. <mailto:smullen@crwf.com>
35. <mailto:shelbyres19@outlook.com>
36. <tel:440-891-9395>
37. <mailto:dianepeplin@hotmail.com>
38. <tel:+41613241111>
39. <mailto:>
40. <tel:1-888-669-6682>
41. <mailto:novartis.email@novartis.com>